Yes I'm really looking forward to adding additional indications. Partnering with John's Hopkins or the FragileX society or a PD group would give a lot of veracity to our claims of developing a CNS platform. I'm also really looking forward to our data being peer review published. There's a lot of money out there for a stock with a CNS platform drug and the more legitimacy added, the closer to fair value we should become.
News 
Market Data 
Discover 
